Bryn Mawr Capital Management LLC Increases Holdings in Zoetis Inc. (NYSE:ZTS)

Bryn Mawr Capital Management LLC increased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 70.8% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 14,888 shares of the company’s stock after acquiring an additional 6,170 shares during the quarter. Bryn Mawr Capital Management LLC’s holdings in Zoetis were worth $2,938,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Blue Bell Private Wealth Management LLC lifted its position in Zoetis by 222.5% during the fourth quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock worth $25,000 after buying an additional 89 shares in the last quarter. Independence Bank of Kentucky increased its stake in Zoetis by 371.4% during the fourth quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock worth $33,000 after acquiring an additional 130 shares during the last quarter. Moisand Fitzgerald Tamayo LLC increased its stake in Zoetis by 105.5% during the third quarter. Moisand Fitzgerald Tamayo LLC now owns 187 shares of the company’s stock worth $33,000 after acquiring an additional 96 shares during the last quarter. Ramirez Asset Management Inc. acquired a new stake in Zoetis during the third quarter worth $35,000. Finally, First Financial Corp IN increased its stake in Zoetis by 57.2% during the fourth quarter. First Financial Corp IN now owns 217 shares of the company’s stock worth $43,000 after acquiring an additional 79 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 3.3 %

Shares of NYSE ZTS traded up $5.06 during trading on Friday, reaching $158.42. The stock had a trading volume of 5,236,447 shares, compared to its average volume of 3,117,213. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.00 and a current ratio of 3.36. The business’s 50-day moving average price is $171.79 and its 200-day moving average price is $179.29. The company has a market cap of $72.45 billion, a P/E ratio of 31.25, a PEG ratio of 2.31 and a beta of 0.85.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). The firm had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.19 billion. Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The company’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.15 earnings per share. On average, equities research analysts predict that Zoetis Inc. will post 5.79 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be issued a $0.432 dividend. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $1.73 dividend on an annualized basis and a yield of 1.09%. Zoetis’s dividend payout ratio (DPR) is presently 34.12%.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 363 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $197.74, for a total transaction of $71,779.62. Following the transaction, the executive vice president now owns 20,417 shares in the company, valued at approximately $4,037,257.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders sold 2,209 shares of company stock worth $371,293. Company insiders own 0.12% of the company’s stock.

Analyst Ratings Changes

ZTS has been the subject of several recent analyst reports. Barclays cut their target price on Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research note on Tuesday. The Goldman Sachs Group raised their target price on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. Piper Sandler reissued an “overweight” rating and set a $195.00 target price (down previously from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Finally, Stifel Nicolaus dropped their price objective on Zoetis from $215.00 to $195.00 and set a “buy” rating for the company in a research note on Tuesday, April 2nd. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $218.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.